Effects of Alendronate on Bone Mineral Density in Men with Prostate Cancer Treated with Androgen Deprivation Therapy

Jan M Bruder, J. Z. Ma, N. Wing, Joseph W Basler, D. Katselnik

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Bone mineral density (BMD) is low in men with prostate cancer treated with androgen deprivation therapy (ADT). Intravenous bisphosphonates have been shown to prevent the bone loss, however, the effectiveness of oral bisphosphonates have not been studied in this population. In this retrospective cohort study, we examine the effect of alendronate on BMD in men with prostate cancer receiving ADT. We reviewed the charts of patients receiving ADT referred from the VA Urology Clinic for BMD measurements. Forty seven patients had follow up BMD measurements (17.6 + 8.3 months). Twenty-two men (47%) were also receiving alendronate 70 mg every week. There was a statistically significant difference (p < 0.05) in the percent change of BMD per year at the spine (- 1.29 ± 0.7% vs. + 1.41 ± 0.7%), total hip (- 0.94 ± 0.6% vs. + 0.97 ± 0.5%), femoral neck (- 2.17 ± 0.7% vs. + 0.32 ± 0.6%) and trochanter (- 2.01 ± 0.7% vs. + 0.79 ± 0.8%) in the patients not treated compared to those treated with alendronate. In the four other measured sites at the radius (proximal, mid, ultra distal and total), there were no statistically significant differences (p > 0.05). These findings confirm that bone loss occurs in men receiving ADT at all sites measured. The use of alendronate prevents bone loss at the spine and hip, but does not seem to have the same protective effect at the radius.

Original languageEnglish (US)
Pages (from-to)431-437
Number of pages7
JournalJournal of Clinical Densitometry
Volume9
Issue number4
DOIs
StatePublished - Oct 2006

Fingerprint

Alendronate
Bone Density
Androgens
Prostatic Neoplasms
Diphosphonates
Bone and Bones
Urology
Therapeutics
Hip
Spine
Cohort Studies
Retrospective Studies
Population

Keywords

  • bisphosphonates
  • hypogonadism
  • men
  • Osteoporosis
  • prostate cancer

ASJC Scopus subject areas

  • Medicine(all)
  • Radiology Nuclear Medicine and imaging

Cite this

Effects of Alendronate on Bone Mineral Density in Men with Prostate Cancer Treated with Androgen Deprivation Therapy. / Bruder, Jan M; Ma, J. Z.; Wing, N.; Basler, Joseph W; Katselnik, D.

In: Journal of Clinical Densitometry, Vol. 9, No. 4, 10.2006, p. 431-437.

Research output: Contribution to journalArticle

@article{99e07003c63d4663b70b0dd0acb71d11,
title = "Effects of Alendronate on Bone Mineral Density in Men with Prostate Cancer Treated with Androgen Deprivation Therapy",
abstract = "Bone mineral density (BMD) is low in men with prostate cancer treated with androgen deprivation therapy (ADT). Intravenous bisphosphonates have been shown to prevent the bone loss, however, the effectiveness of oral bisphosphonates have not been studied in this population. In this retrospective cohort study, we examine the effect of alendronate on BMD in men with prostate cancer receiving ADT. We reviewed the charts of patients receiving ADT referred from the VA Urology Clinic for BMD measurements. Forty seven patients had follow up BMD measurements (17.6 + 8.3 months). Twenty-two men (47{\%}) were also receiving alendronate 70 mg every week. There was a statistically significant difference (p < 0.05) in the percent change of BMD per year at the spine (- 1.29 ± 0.7{\%} vs. + 1.41 ± 0.7{\%}), total hip (- 0.94 ± 0.6{\%} vs. + 0.97 ± 0.5{\%}), femoral neck (- 2.17 ± 0.7{\%} vs. + 0.32 ± 0.6{\%}) and trochanter (- 2.01 ± 0.7{\%} vs. + 0.79 ± 0.8{\%}) in the patients not treated compared to those treated with alendronate. In the four other measured sites at the radius (proximal, mid, ultra distal and total), there were no statistically significant differences (p > 0.05). These findings confirm that bone loss occurs in men receiving ADT at all sites measured. The use of alendronate prevents bone loss at the spine and hip, but does not seem to have the same protective effect at the radius.",
keywords = "bisphosphonates, hypogonadism, men, Osteoporosis, prostate cancer",
author = "Bruder, {Jan M} and Ma, {J. Z.} and N. Wing and Basler, {Joseph W} and D. Katselnik",
year = "2006",
month = "10",
doi = "10.1016/j.jocd.2006.07.005",
language = "English (US)",
volume = "9",
pages = "431--437",
journal = "Journal of Clinical Densitometry",
issn = "1094-6950",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Effects of Alendronate on Bone Mineral Density in Men with Prostate Cancer Treated with Androgen Deprivation Therapy

AU - Bruder, Jan M

AU - Ma, J. Z.

AU - Wing, N.

AU - Basler, Joseph W

AU - Katselnik, D.

PY - 2006/10

Y1 - 2006/10

N2 - Bone mineral density (BMD) is low in men with prostate cancer treated with androgen deprivation therapy (ADT). Intravenous bisphosphonates have been shown to prevent the bone loss, however, the effectiveness of oral bisphosphonates have not been studied in this population. In this retrospective cohort study, we examine the effect of alendronate on BMD in men with prostate cancer receiving ADT. We reviewed the charts of patients receiving ADT referred from the VA Urology Clinic for BMD measurements. Forty seven patients had follow up BMD measurements (17.6 + 8.3 months). Twenty-two men (47%) were also receiving alendronate 70 mg every week. There was a statistically significant difference (p < 0.05) in the percent change of BMD per year at the spine (- 1.29 ± 0.7% vs. + 1.41 ± 0.7%), total hip (- 0.94 ± 0.6% vs. + 0.97 ± 0.5%), femoral neck (- 2.17 ± 0.7% vs. + 0.32 ± 0.6%) and trochanter (- 2.01 ± 0.7% vs. + 0.79 ± 0.8%) in the patients not treated compared to those treated with alendronate. In the four other measured sites at the radius (proximal, mid, ultra distal and total), there were no statistically significant differences (p > 0.05). These findings confirm that bone loss occurs in men receiving ADT at all sites measured. The use of alendronate prevents bone loss at the spine and hip, but does not seem to have the same protective effect at the radius.

AB - Bone mineral density (BMD) is low in men with prostate cancer treated with androgen deprivation therapy (ADT). Intravenous bisphosphonates have been shown to prevent the bone loss, however, the effectiveness of oral bisphosphonates have not been studied in this population. In this retrospective cohort study, we examine the effect of alendronate on BMD in men with prostate cancer receiving ADT. We reviewed the charts of patients receiving ADT referred from the VA Urology Clinic for BMD measurements. Forty seven patients had follow up BMD measurements (17.6 + 8.3 months). Twenty-two men (47%) were also receiving alendronate 70 mg every week. There was a statistically significant difference (p < 0.05) in the percent change of BMD per year at the spine (- 1.29 ± 0.7% vs. + 1.41 ± 0.7%), total hip (- 0.94 ± 0.6% vs. + 0.97 ± 0.5%), femoral neck (- 2.17 ± 0.7% vs. + 0.32 ± 0.6%) and trochanter (- 2.01 ± 0.7% vs. + 0.79 ± 0.8%) in the patients not treated compared to those treated with alendronate. In the four other measured sites at the radius (proximal, mid, ultra distal and total), there were no statistically significant differences (p > 0.05). These findings confirm that bone loss occurs in men receiving ADT at all sites measured. The use of alendronate prevents bone loss at the spine and hip, but does not seem to have the same protective effect at the radius.

KW - bisphosphonates

KW - hypogonadism

KW - men

KW - Osteoporosis

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=33750607172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750607172&partnerID=8YFLogxK

U2 - 10.1016/j.jocd.2006.07.005

DO - 10.1016/j.jocd.2006.07.005

M3 - Article

C2 - 17097529

AN - SCOPUS:33750607172

VL - 9

SP - 431

EP - 437

JO - Journal of Clinical Densitometry

JF - Journal of Clinical Densitometry

SN - 1094-6950

IS - 4

ER -